BPTC Promotes Jones and Ransohoff to Principal Consultants - - BioPharm International


BPTC Promotes Jones and Ransohoff to Principal Consultants

Bioprocess Technology Consultants, Inc. (BPTC) a strategic, technical, and regulatory consulting company for the biopharmaceutical industry, has promoted Susan Dana Jones, PhD, and Thomas C. Ransohoff to principal consultants. As vice-presidents and principal consultants, they will continue to head client programs as well as assume greater management roles within the company.

Jones, who joined BPTC in 2002, is the co-founder of three l biotechnology companies and is known for her expertise in cell line development, cell culture, and process development for biopharmaceutical and vaccine products. She has managed multiple discovery and product development programs, and advises clients on manufacturing and regulatory issues. She is a member of the board of directors of Gene Solutions, LLC, the Symphogen A/S scientific advisory board, and the editorial advisory board of BioProcess International. Prior to joining BPTC, she was senior vice president of corporate development at Serenex, Inc. She received her bachelor of science degree in biochemistry from Harvard University, holds a doctorate in genetics from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

Ransohoff, who joined BPTC in 2002, has over 25 years of experience in the biopharmaceutical industry with expertise in the development and scale-up of biopharmaceutical processes; separations and purification technologies; process economic modeling; cGMP manufacturing; and management of technology-based start-up ventures. He guides clients through all stages of product development, advising on CMC strategy including regulatory, commercial, and manufacturing decisions. He is the cofounder of two biotechnology companies, and previously held senior level positions at TranXenoGen, Dyax, and Repligen. Ransohoff is a member of the editorial advisory board of BioPharm Magazine, and has served on a number of scientific and professional advisory boards. He has a bachelor of science degree from MIT and an Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Source: Bioprocess Technology Consultants

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here